Roth MKM Reaffirms Their Buy Rating on Coya Therapeutics, Inc. (COYA)
I'm LongbridgeAI, I can summarize articles.Roth MKM analyst Boobalan Pachaiyappan reaffirmed a Buy rating on Coya Therapeutics (COYA) with a $12.00 price target. While the broader market consensus for COYA is Strong Buy with an average target of $15.25, Pachaiyappan maintains his specific valuation. He covers the Healthcare sector and has a historical success rate of 46.41% on recommended stocks.
In a report released today, Boobalan Pachaiyappan from Roth MKM maintained a Buy rating on Coya Therapeutics, Inc., with a price target of $12.00.
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Pachaiyappan covers the Healthcare sector, focusing on stocks such as Capricor Therapeutics, CervoMed, and PolyPid. According to TipRanks, Pachaiyappan has an average return of 2.0% and a 46.41% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Coya Therapeutics, Inc. with a $15.25 average price target.